Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial

BACKGROUND: Global randomised controlled trials of the anti-IL-6 receptor antibody tocilizumab in patients admitted to hospital with COVID-19 have shown conflicting results but potential decreases in time to discharge and burden on intensive care. Tocilizumab reduced progression to mechanical ventil...

Descripción completa

Detalles Bibliográficos
Autores principales: Soin, Arvinder S, Kumar, Kuldeep, Choudhary, Narendra S, Sharma, Pooja, Mehta, Yatin, Kataria, Sushila, Govil, Deepak, Deswal, Vikas, Chaudhry, Dhruva, Singh, Pawan Kumar, Gupta, Ashish, Agarwal, Vikas, Kumar, Suresh, Sangle, Shashikala A, Chawla, Rajesh, Narreddy, Suneetha, Pandit, Rahul, Mishra, Vipul, Goel, Manoj, Ramanan, Athimalaipet V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078880/
https://www.ncbi.nlm.nih.gov/pubmed/33676589
http://dx.doi.org/10.1016/S2213-2600(21)00081-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078880/
https://www.ncbi.nlm.nih.gov/pubmed/33676589
http://dx.doi.org/10.1016/S2213-2600(21)00081-3

Ejemplares similares